Dispute With Departing Board Member Creates Speculation BioMarin Is For Sale
This article was originally published in The Pink Sheet Daily
Executive Summary
Dueling letters pose question of whether there has been a bona fide offer for the ERT-focused specialty firm.
You may also be interested in...
BioMarin Launches Firdapse In Germany And The UK
Biomarin's fourth orphan product, amifampridine, launched for the symptomatic treatment of Lambert Eaton myasthenic syndrome.
BioMarin Launches Firdapse In Germany And The UK
Biomarin's fourth orphan product, amifampridine, launched for the symptomatic treatment of Lambert Eaton myasthenic syndrome.
Pfizer Partners With Protalix On Gaucher Drug Eyeing Lower Cost Plant-Based Production
Pfizer agrees to pay $60 million upfront for rights to taliglucerase, an investigational competitor to Genzyme's Cerezyme.